May 8, 2017
Ipsen buys five Sanofi’s products
Ipsen has completed acquisition of a portfolio of five consumer healthcare products from Sanofi.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Sanofi
April 28, 2017
Sanofi kicks off year with robust growth driven by Specialty Care and Vaccines
Sanofi Chief Executive Officer, Olivier Brandicourt, said that the company has started the year with robust growth driven by Specialty Care and Vaccines as well as good performance in Emerging Markets.
April 28, 2017
US FDA to review biologics license application resubmission for Kevzara
Sanofi and Regeneron Pharmaceuticals have resubmitted their Biologics License Application for Kevzara, which is an investigational human monoclonal antibody to be used for treatment of rheumatoid arthritis (RA) with adult patients.
April 24, 2017
CHMP gives positive opinion for Sanofi’s and Regeneron’s rheumatoid arthritis drug
European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for the marketing authorization of Sanofi and Regeneron Pharmaceuticals joint developed product Kevzara (sarilumab), recommending its approval for use in adult patients with moderately to severely active rheumatoid arthritis.
April 5, 2017
Sanofi welcomes new EVP
Sanofi has appointed Bill Sibold, a current head of Sanofi Genzyme’s Global Multiple Sclerosis, Oncology and Immunology organization, as Executive Vice President Sanofi Genzyme and member of the Executive Committee, effective July 1, 2017.
April 5, 2017
Sanofi’s partner JHL Biotech accepted for clinical trial in China
JHL Biotech said Wednesday its Clinical Trial Application (CTA) for use of its first product in pipleine, JHL1101 in Phase 1 and Phase 3 clinical trials in Non-Hodgkin’s Lymphoma patients has been accepted by the China Food and Drug Administration (CFDA).
March 23, 2017
Crunch week looms for Sanofi, Roche and GSK at U.S. drugs agency
Three of Europe’s top drugmakers face critical verdicts from U.S. regulators next week, with Sanofi <SASY.PA> and Roche <ROG.S> likely to win approvals for two new products, while GlaxoSmithKline <GSK.L> braces for a potential generic rival.
March 15, 2017
Severe asthma market is driving Nucala sales, opportunity for Teva, AstraZeneca, Sanofi, and Regeneron
Decision Resources Group (DRG) finds that Nucala’s novel mechanism of action and specific indication for eosinophilic asthma are key drivers behind the agent’s recent success in the severe asthma market.
March 14, 2017
Market analyst puts focus on four major players in the Drug Manufacturers space
Ahead of Tuesday’s trading session, Stock-Callers.com puts focus on four major players in the Drug Manufacturers space.
March 3, 2017
Sanofi, AstraZeneca making Respiratory Syncytial Virus vaccine
Sanofi’s vaccines global business unit Sanofi Pasteur has signed a deal with AstraZeneca’s biologics bramch MedImmune, to make and sell a monoclonal antibody-called MEDI8897-for the prevention of the most common reason for lower respiratory tract infections in newborns and infants, Respiratory Syncytial Virus (RSV).